MTOR and cancer: Preclinical studies of rapamycin in mice as well as recent data using novel and approved rapalogs (Ridaforolimus, Ariad; Temsirolimus, Wyeth) [12] in human patients suggest that mTOR blockade may be active in several cancers including sarcoma [2], [13], [14], [15], [16].